---
title: "Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294957966.md"
description: "Entrada Therapeutics reported Q2 2026 results with $898K collaboration revenue, a net loss of $42.76M, and diluted EPS of ($1.01). Clinical programs for DMD are advancing, with safety endpoints met in Cohort 1. The Vertex partnership on VX-670 is progressing, with results expected in H2 2026. The company holds $223M in cash, sufficient to fund operations through Q3 2027."
datetime: "2026-08-05T11:21:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294957966.md)
  - [en](https://longbridge.com/en/news/294957966.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294957966.md)
generator: "portal-rs"
---

# Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary

Entrada Therapeutics, Inc. reported second-quarter 2026 results in its 10-Q showing collaboration revenue of $898K, a net loss of ($42.76M) and diluted loss per share of ($1.01), compared with $1.95M revenue, a ($43.1M) net loss and ($1.04) diluted loss per share in the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$898K

$1.95M

(53.9%)

Net income²

($42.76M)

($43.1M)

0.8%

Diluted EPS³

($1.01)

($1.04)

2.9%

*¹ Reported as “Collaboration revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”.*

**Business Highlights**

-   Clinical advancement across multiple DMD programs (ELEVATE-44/45/50/51): Cohort 1 (6 mg/kg) completed and met safety endpoints with statistically significant functional improvements correlated with increased dystrophin; additional cohorts and open-label extensions are ongoing with planned readouts through 2027.
-   Partnerships and pipeline: Collaboration with Vertex on VX-670 progressing with MAD dosing; results expected in H2 2026. Ocular program ENTR-801 selected, with a second ocular candidate planned for H2 2026.
-   Liquidity and operations: Cash resources of $223M as of June 30, 2026 are expected to fund operations into Q3 2027; R&D spending is focused on clinical execution and manufacturing scale-up.

Original SEC Filing: Entrada Therapeutics, Inc. \[ TRDA \] - 10-Q - Aug. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TRDA.US](https://longbridge.com/en/quote/TRDA.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Bioventures 2018 L.P. Mpm Sells 192,500 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock](https://longbridge.com/en/news/298520100.md)
- [TRDA: Upcoming clinical data and platform safety position the company for accelerated approval and market growth](https://longbridge.com/en/news/298492693.md)
- [Definitive discloses TRA holders waive early termination payment for qualifying change of control through Dec 31, 2026](https://longbridge.com/en/news/298459372.md)
- [El.En. announces filing of H1 2026 interim financial report as of June 30](https://longbridge.com/en/news/298698626.md)
- [Tractor Supply declares R$ 0.05 per-unit dividend for Q3 2026](https://longbridge.com/en/news/298615733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**